
YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at th…
SVRA is up 7.11% today. Volume is 3.44M vs a 30-day average of 2.42M (1.42x).
Savara, Inc. is scheduled to report earnings Thu, Nov 5, 2026 · after close. Analysts expect EPS of $-0.17. Stocks often move sharply on earnings day.

YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at th…
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the CHEST 2026 Annual Meeting in Ph…

Savara Inc. announced that CHEST 2026 accepted an encore oral presentation on Phase 3 IMPALA-2 data and a poster on Phase 2/3 IMPALA molgramostim data in autoimmune pulmonary alve…